It is used in patients whose cancer has metastasized (spread) to the bones and is causing symptoms but has not spread to other organs. In this paper we extensively review the literature on the use of radium-223 dichloride in metastatic castration-resistant prostate cancer.īone metastasis Overall survival Radium-223 dichloride α-Emitters. Radium 223 dichloride is approved to treat: Prostate cancer that is castrate resistant (has not responded to treatments that lower testosterone levels). Each mL of solution contains 1100 kBq (29.7 microcurie) radium Ra 223 dichloride (radium-223 dichloride), corresponding to 0.58 ng radium-223, at the reference date. Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. The therapeutic landscape of metastatic skeletal cancer significantly changed after the introduction of radium-223, the first bone-homing radiopharmaceutical with disease-modifying properties. XOFIGO (radium Ra 223 dichloride) is a therapeutic alpha particle-emitting pharmaceutical with targeted anti-tumour effect on bone metastases. Make your tax-deductible gift and be a part of the cutting-edge research and care thats changing medicine. Many studies in recent decades have demonstrated the efficacy of various radiopharmaceuticals, including strontium-89 and samarium-153, for palliation of pain from diffuse skeletal metastases, but no significant benefit in terms of disease progression and overall survival has been shown. Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer. Radium Ra 223 Dichloride (Intravenous Route) Your gift holds great power donate today Donate. The current therapeutic armamentarium includes conventional analgesics, chemotherapeutic agents, immunotherapy, androgen-deprivation therapy, osteoclast inhibitors (bisphosphonates, denosumab), surgical interventions, external-beam radiotherapy and radionuclide metabolic therapy. The active substance in Xofigo, radium-223, emits short-range radiation known as alpha particles.

The onset of skeletal metastases is typical of advanced-stage prostate cancer and requires a multidisciplinary approach to alleviate bone pain and try to delay disease progression. Radium-223 dichloride (Radium-223) is a novel targeted radioisotope that, as a bone-seeking calcium mimetic, selectively binds mineral hydroxyapatite of newly formed bone stroma in areas of increased metabolic activity as bone metastases.